Despite recent advances in immunotherapy for ESCC, such as immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis, identifying patients who may benefit remains a challenge [15, 16]. Here, CD274 is linked to esophageal squamous cell carcinoma.